All IndicationsPhase 3Phase 3Phase 3Phase 2Phase 2
Congenital Adrenal Hyperplasia
3
Companies
5
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
PHM.MC
PharmaMar, S.A.
Chronocort
CRNX
Crinetics Pharmaceuticals, Inc.
Atumelnant
VRTX
Vertex Pharmaceuticals Incorporated
Atumelnant
CRNX
Crinetics Pharmaceuticals, Inc.
atumelnant (CRN04894)
VRTX
Vertex Pharmaceuticals Incorporated
atumelnant (CRN04894)
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| PHM.MC PharmaMar, S.A. | Chronocort | Phase 3 | — | — | — |
| CRNX Crinetics Pharmaceuticals, Inc. | Atumelnant | Phase 3 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | Atumelnant | Phase 3 | — | — | — |
| CRNX Crinetics Pharmaceuticals, Inc. | atumelnant (CRN04894) | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | atumelnant (CRN04894) | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
3
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.
